Delcath Systems, Inc. ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it ...
1d
State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth ...
Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...
Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...
The company projects plozasiran to generate $2 billion to $3 billion annually in the SHTG market alone, with Phase III studies (SHASTA-3, SHASTA-4, and MUIR 3) expected to complete enrollment this ...
Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, ...
Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback